

Index to Volume 3

Author Index

Addiego, J. E., S160
Ahn, C. H., 1028
Ahn, S., 1028
Ahn, S. S., 1028
Aisenberg, A. C., S144
Allegro, G. M., 98
Allo, M., S273
Ammann, A. J., S160, S179
Amsbaugh, D. F., 332
Andrews, C., S108
Aranda, C., S183
Armstrong, J., S273
Ashbaugh, P., 914
Austrian, R., 183, S1
Bailey, M. C., 1035
Baker, P. J., 332
Bando, K., 885
Barrett, D. J., S179
Bartlett, J. G., 535
Bartlett, M. S., 1139
Bastille, A., 84
Bates, J. H., 949
Beauchamp, D., 84
Bentley, D. W., S61, S71
Berberich, F. R., S133
Bergan, T., 45, 396
Bergeron, M. G., 84
Berwald, L. G., 871, 1024
Bodey, G. P., S259
Brachman, P. S., 640, 783
Bratton, L., S113
Brennan, P. J., 905
Brennan, R. O., 98
Brook, I., 470
Broome, C. V., 277, S82
Brown, W., 154
Browne, R., S273
Brummett, R. E., S216
Bullen, J. J., 1127
Bundtzen, R. W., 28
Caldes, G., 332
Campbell, S. C., 150
Carlson, A. J., Jr., S31
Cave, M. D., 949
Chakraborty, A. K., 1060
Chap, T. L., S168
Chaparas, S. D., 934
Cherubin, C. E., 1105
Chodosh, S., 140
Christianson, L., S183
Citron, D. M., 599
Clahsen, J., 117
Cohen, M. S., 565
Cohn, D. L., 28
Collins, F. M., 981
Content, J., 1186
Coonrod, J. D., 310
Corpe, R. F., 1064
Cosio, F. G., S168
Counts, G., 166
Cox, R. S., S133
Craig, W. A., 1, 28, 171
Crawford, J. T., 949
Cruse, P., 734
Cunha, B. A., S269
Dalovisio, J. R., 1068
Damle, P. B., 1060
David, H. L., 878
Davidson, P. T., 816, 973, 1052, 1060
Davis, A. L., S183
Davis, B. I., 132
De Clercq, E., 1186
Delgin, J. M., S269
Deryck, R., 1186
Devos, R., 1186
Digranes, A., 125, 396
Donaldson, S. S., S133
Donowitz, L. G., 701, 716
Douglas, R. M., 233
Ebright, J., S273
Edwards, L., 166
Egger, M. J., 492
Egoz, N., 649
Eickhoff, T. C., 798
Engel, H. W. B., 871, 1024
Epstein, L., 785
Facklam, R. R., 277
Faich, G., 683
Falkingham, J. O., III, 990
Feder, H. M., Jr., 479
Fekety, R., S273
Fiers, W., 1186
File, T. M., Jr., 121, 154
Finegold, S. M., 150, 599
Finland, M., 354, 812
Fisch, G. R., S113
Fisher, K. A., 708, 716
Fraser, B. A., 323
Freeman, J., 658, 668
Gallin, J. I., 1196
Gangadharam, P. R., 973
Garcia, E., 212
Gentry, L. O., 150, 166
George, W. L., 599
Geraci, J. E., S250
Gerber, A. U., 28, 171
Giebink, G. S., 342, S43, S168
Ginsberg, M. B., 683
Ginsburg, C. M., 117
Gleason, C., 154
Glenn, J., 1151
Goble, M., 1052
Gorbach, S. L., 535
Greenblatt, D. J., S230
Griffith, R. S., S200
Gröschel, D. H., 1251
Gruft, H., 990
Gump, D. W., S289
Ha, K., S71
Hahn, H., 1221
Haley, R. W., 781, 783
Havelar, A. H., 1024
Haverkamp, J., 871
Hellum, K. B., 125, 396
Helms, K. K., 166
Hilleman, M. R., S31
Himes, E. M., 960
Holbrook, K., 683
Hornick, R. B., 1251
Howie, V. M., S119
Hoyt, J. W., 701
Hsu, K. H. K., 1075
Hurst, G. A., 1028
Igra-Siegnan, Y., 397
Iravani, A., 159
Ito, T., 997
Izard, M. W., S269
Jenkins, P. A., 862, 1021
Jenner, E. A., 770
Johnston, R. B., Jr., 282
Jones, D. B., 898, 1068
Jørgensen, J. B., 979
Kallings, J. O., 721
Kamforin, L. E., 408, 1104
Kaminski, Z. C., 397
Kapila, R., 397
Kaplan, H. S., S133
Karasseva, V., 1040, 1081
Karczag, E., 1040
Karlson, A. G., 960
Karma, P., S124
Kaufmann, S. H. E., 1221
Kawakami, K., 997
Khanijo, V., 1052
King, T. C., 627
Kirby, B. D., 599
Kirby, W. M. M., 1, S236
Kishore, R., 1179
Kita, N., 997
Klastersky, J., 74
Kleberg, H. H., 1008
Klein, J. O., 246, S113
Kondo, H., 997
Kornfeld, S. J., 521
Korzeniowski, O. M., 98
Kottek, S. S., 636
Kovaleva, T. P., 408, 1104
Krogstad, D. J., 627, S230
Kubar, O. I., 408, 1104
Kunin, C. M., 4, 745
Kurasawa, T., 885
Kuse, A., 997

Kuze, F., 885
Lagrange, P. H., 422
Landesman, S. H., S184
Le, C. T., S43
Lee, C.-J., 323, S51
Lee, Y., 885
LeFrock, J. L., 159
Leinonen, M., S124
Levine, J. I., 701
Lin, K.-J., 323
Lin, K.-T., S51
Lindeboom, B. W., 1024
Lopez, R., 212
Louie, T. J., 535
Louria, D. B., 397
Lowbury, E. J. L., 728
Lowell, J. R., 1028
Lusk, R., S273
Mackowiak, P. A., 508
Maderazo, E. G., 479
Maekawa, N., 885
Maesen, F. P. V., 132
Magnusson, M., 944
Mäkelä, P. H., S124
Mamot, K., S71
Mankiewicz, E., 926
Marisk, F. J., 716
Martone, W. J., 701, 708
Mathieu, O. R., S113
Matsuda, N., 997
Mattie, H., 19
McCalmon, R. T., 1060
McCarthy, C., 914
McClatchy, J. K., 867
McConnell, K. B., S108
McCracken, G. H., Jr., 117, S282
McDonald, P. J., 38
McGowan, J. E., Jr., 658, 668, 760, 790
McLean, A. A., S31
Meissner, G., 813, 953
Miao, L., 683
Michaeli, D., 649
Michel, J., 678, 754
Miller, G. B., 701
Moellerling, R. C., Jr., S230
Mogabgab, W., 150, 159
Mombelli, G., 74
Moon, D., S71
Moore, L., S71
Moulding, T. S., 1052
Moxon, E. R., 354
Nakajima, N., 997
Nel, E. E., 1013
Nelson, J. D., S282
Neu, H. C., 12, 110
Neumann, H. H., 1255
Nightingale, C. H., S269
Onderdonk, A. B., 535
Osier, C., 479
Osterman, C. A., 701, 708
Pankey, G. A., 154, 1068
Parker, B. C., 990
Paacock, J. E., Jr., 701
Pennington, J. E., 67
Pezzia, W., 1035
Pfeiffer, R. R., S205
Plaut, A. G., 521
Ploussard, J. H., S119
Poirier, A., 84
Poletto, P., S71
Porter, P. J., S113
Pratt, P. F., 973
Prescott, B., 332
Pruul, H., 38
Pukander, J., S124
Quintiliani, R., S269
Ramakrishnan, C. V., 1090
Raleigh, J. W., 1035
Remaut, E., 1186
Remington, J. S., 492
Richard, G. A., 159
Rifkin, G., S273
Riley, I. D., 233
Ronda, C., 212
Root, R. K., 565
Rosenberg, E. W., 170
Rosenzweig, D. Y., 1046
Rudensky, B., 754
Runyon, E. H., 819, 1098
Sabin, A. B., 548
Sacks, T., 635, 678, 754
Salstrom, S.-J., 121
Saman, E., 1186
Sande, M. A., 98, 701, S240
Sansonet, P., 422
Schaad, U. B., S282
Scheld, W. M., 98
Schiffman, G., 224, S18, S97, S108, S133, S160, S168, S183, S184
Schlessinger, D., 637
Schlueter, D. P., 1046
Schreiner, A., 125, 396
Sell, S. H., S97, S108
Semmelweis, I. P., 808
Sen, P., 397
Shapiro, M., 678, 754
Shimoide, H., 997
Shirota, N., 997
Siber, G. R., S144
Silva, J., S273
Silverblatt, J., 1035
Simchen, E., 678, 683, 754
Simpson G. L., 492
Sjögren, I., 1084
Skatrud, J., 150
Sloyer, J. L., Jr., S119
Sparling, P. F., 166
Spika, J. S., S43, S168
Springett, A., S71
Sriyabaya, N., 1085
Stanssens, P., 1186
Starobin, S. G., S113
Stashak, P. W., 332
Stinson, E. B., 492
Sutter, V. L., 599
Szu, S., 323
Tager, I. B., 683
Tamura, M., 997
Tan, J. S., 121
Tarlin, L. D., S113
Tavernier, J., 1186
Teele, D. W., S113
Terry, B. A., 738
Thoen, C. O., 960
Thompson, J., S97
Thys, J. P., 74
Tight, R. R., 1139
Timpe, A., 1098
Tomasz, A., 190, 267
Toshniwal, R., S273
Toth, E. A., 1035
Tsukamura, M., 829, 841, 997
Turnipseed, S. A., S224
Vaughn, W. K., S97, S108
Vella, P. P., S31
Volckaert, G., 1186
Vosti, K. L., S133
Wagner, K. F., 166
Wallace, R. J., Jr., 898, 1068
Wara, D. W., 299, S160
Wara, W. M., S160
Ward, J., 254
Watanakunakorn, C., S210
Watson, S. R., 981
Wayne, L. G., 822
Weibel, R. E., S31
Weiszfeiler, J. G., 1040, 1081
Weitzman, S. A., S144
Wenzel, R. P., 701, 708, 716
Wetherall, B. L., 38
Wieten, G., 871
Wilson, W. R., S250
Winkelstein, J. A., 289
Wise, R. I., S199, S293
Wiss, K., 898
Wold, J. S., S224
Wolinsky, E., 1025
Wongwatana, S., 1085
Woodhour, A. F., S31
Wright, P. F., S97, S108
Yamamoto, Y., 997
Yoneda, K., 310
Yoshimoto, K., 997
Younes, R. P., S113
Zak, O., 98
Zigelboim, S., 267
Zlydenkov, D. M., 408, 1104
Zweighaft, T., 117

Subject Index

Actinomycetoma
case report and literature review, 1139
surgical and medical therapy for, 1139

Amikacin, for treatment of infection with *M. fortuitum* and *M. chelonei*, 1068

Aminoglycosides
intermittent vs. continuous administration, 74, 84
in treatment of bronchopulmonary infections due to gram-negative bacteria, 74

Ampoxicillin
vs. bacampicillin in treatment of urinary tract infection, 159
levels in human blood and interstitial fluid after iv administration, 121

Ampicillin
and bacampicillin, pharmacokinetics in infants and children, 117
vs. bacampicillin in treatment of bacterial infections of lower respiratory tract, 150
vs. bacampicillin in treatment of gonorrhea, 166
four times daily vs. bacampicillin twice daily in treatment of bronchitis, 140
levels in human blood and interstitial fluid after iv administration, 121

Antibiotic levels, in human blood and interstitial fluid after administration of drugs, 121

Antibiotic prophylaxis for prevention of infection in cancer patients, in combination with use of protected environments, S259

Antibiotic resistance, of *Salmonella*, 1105

Antibiotic-associated enterocolitis
in hamsters, S273
treatment with vancomycin, S273

Antibiotics. *See also* Antimicrobial agents; *names of specific agents*
evaluation of usage in hospitals, 745
penetration into respiratory secretions, 67
for surgical prophylaxis, 745, 754

Antigens
human leukocyte, association with *M. intracellulare* disease, 1060
typing, structures of, for atypical mycobacteria, 905

Antimicrobial agents. *See also* Antibiotics; *names of specific agents*
assessment of combinations, 627
continuous vs. intermittent administration
therapy of *S. pneumoniae* meningitis in rabbits, and post-antibiotic effect, 98
tissue penetration and efficacy, 84
in treatment of bronchopulmonary infections due to gram-negative bacteria, 74
dosage schedules and pharmacokinetics
historical review, 4
in infections at different sites, 12
efficacy of 29 regimens in experimental intraabdominal sepsis, 535
kinetics of action, 19
pharmacokinetics of tissue penetration, 45

Bacampicillin
administered twice daily, worldwide experience, 171
vs. amoxicillin
for skin and soft tissue infections, 170
in treatment of urinary tract infections, 159
and ampicillin, in infants and children, 117
vs. ampicillin, penicillin V, and amoxicillin in treatment of tonsillitis and/or pharyngitis due to β -hemolytic streptococci, 154
vs. ampicillin, in treatment of bacterial infections of lower respiratory tract, 150
levels in human blood and interstitial fluid after oral administration, 121
pharmacokinetics, 110
of ampicillin in serum and dermal suction blisters after oral administration, 125
pulse dosing in treatment of acute exacerbations of chronic bronchitis, 132
single dose, vs. ampicillin in treatment of gonorrhea, 166
twice daily, vs. ampicillin four times daily in treatment of bronchitis, 140

Bacille Calmette-Guérin, use in study of phage conversion and immunogenic potential, 926

Bacteremia, *Klebsiella*, in newborn intensive care unit, caused by contaminated breast milk, 716

Bronchial secretions, penetration of antibiotics, 67

Bronchitis, antibiotic therapy and pharmacokinetics, 67, 74, 84, 132, 140

Burn units, and nosocomial infections, 721, 728

Cell-mediated immunity
to *M. leprae*, 422
role in bacterial infections, 1221

Chemotaxis, abnormal phagocytic, 1196

Chloramphenicol, current usage, efficacy, toxicity, and susceptibilities of pathogens, 479

Chlorination of water, alternatives to, 1255

Complement, role in defense against *S. pneumoniae*, 289, 310

Cytomegalovirus infections following renal transplantation, review, 1151

Diabetes mellitus, and response to pneumococcal polysaccharide vaccine, S184

Doxycycline, for treatment of infection with *M. fortuitum* and *M. chelonei*, 1068

Drug resistance, patterns and mechanisms in atypical mycobacteria, 878

Endocarditis, staphylococcal and streptococcal, treatment with vancomycin, S250

Eosinophils and neutrophils, human, microbicidal mechanisms, 565

Epidemiology, of atypical mycobacterial infection
lung disease
due to nontuberculous mycobacteria in Japan, 997
in South India, 1090
in Thailand, 1085

M. avium-intracellulare serovars in South Africa, 1013

M. kansasi infections in The Netherlands, 1024

mycobacteriosis in eastern United States, 990

nontuberculous infections in Sweden, 1084

I
N
D
E
X

JMI

nontuberculous mycobacteria in South Africa, 1008
use of seroagglutination test, 867

Epidemiology, of *S. pneumoniae* disease, 233, 277
in infants and children, 246
with antibiotic-resistant pneumococci, 254, 267

Fever, effects on pathogenic microorganisms, teleologic implication, 508

Genetic agents causing variation in mycobacteria, 926

Gonorrhea, bacampicillin vs. ampicillin therapy, 166

Gram-negative anaerobic bacilli, role in infection and susceptibility to antimicrobial agents, *Fusobacterium* and other genera, 599

Hodgkin's disease, response of patients to pneumococcal polysaccharide antigen, S133, S144, S160

IgA proteases, bacterial, and secretory immunity, 521

Immunity
cell-mediated
to *M. leprae*, 422
role in bacterial infections, 1221
and pneumococcal polysaccharide vaccines, S1-S197
secretory, and bacterial IgA proteases, 521
to *S. pneumoniae*
in mice and humans, 224
protection and pathogenesis of tissue damage, 282
response to polysaccharide antigens, 224, 323
regulation by thymus-derived cells, 332
role of complement, 289, 310
role of opsonins, 310
role of spleen, 224, 299
vaccination of chinchillas, 342

Immunocompromised hosts (cardiac allograft recipients), nodal infections, 492

Immunoelectrophoresis, modified rocket- and cross-, study of antigenic relationships among mycobacteria, 934

Immunosuppression, and response to pneumococcal polysaccharide antigen, S160, S168

Infections, bacterial
bronchopulmonary, antibiotic therapy and penetration into bronchial secretions, 67, 74
role of levels of lactic acid in body fluids in detection, 470

Influenza, therapy and prophylaxis with rimantadine, studies in USSR, 408

Intensive care units, nosocomial infections, 716, 721

Interferon, human fibroblast, isolation and characterization of gene and its expression in *Escherichia coli*, 1186

Iron, significance in infection, 1127

Isotopes, comparison of ^{14}C , ^{32}P , ^{33}C , and ^{75}Se for labeling microorganisms, 1179

Klebsiella, bacteremia in newborn intensive care unit, caused by contaminated breast milk, 716

Lactic acid, levels in body fluids, role in detection of bacterial infection, 470

Leprosy, spectrum of disease and immunology, 422

Leukocyte enhancement, increased susceptibility of antibiotic-treated bacteria to leukocytes, 38

Lung infection
with atypical mycobacteria, immune responses, 981
chronic obstructive, response of patients to pneumococcal polysaccharide vaccine, S183
due to *M. avium-intracellulare*, 1046
spectrum of disease, 1046

surgical management, 1064
due to *M. kansasii*
efficacies of various drugs, 1028
treatment with rifampin, 1035

due to nontuberculous mycobacteria, epidemiology in Japan, 997

role of atypical mycobacteria, 1090, 1098 (classic paper), 1085

surgical management of infection with *M. avium-intracellulare*, 1064

Lymphadenitis, diagnosis and treatment, 1075

Malignancies, and spleen, role in immune response to *S. pneumoniae* polysaccharide antigens, 224

Mass spectrometry, pyrolysis techniques, use in taxonomy and identification of mycobacteria, 871

Meningitis, bacterial, treatment with vancomycin, alone and in combination, S289, S293

Mycobacteria
agents causing variation, 926
antigenic relationships studied by modified-rocket and crossed immunoelectrophoresis, 934
definition of terms, 816, 819
epidemiology of opportunist infections in Wales, 1021
infections due to two or more species, 1081
methods of identification and differentiation, 841
numerical, 822, 829
lipid analysis for speciation, 862
pyrolysis mass spectrometry, 871
sensitins, 944
thin-layer chromatography, 862

nontuberculous, epidemiology
of lung disease in Japan, 997
in South Africa, 1008
in Sweden, 1084
use of seroagglutination test, 867
overview, 819

Mycobacteria, atypical. *See also species names*
animal models in study of infection, 953
differentiation from tuberculous infections, 1075
disease in domestic and exotic animals, 960
epidemiology in eastern United States, 990
infections in children, 1075
lung infection, immune response to, 981
pathogenicity and immunogenicity for calves, 979
patterns and mechanisms of multiple-drug resistance, 878
role in human lung disease, 1085, 1090, 1098 (classic paper)
structures of typing antigens, 905
susceptibility
to antituberculous drugs, 885
to various drug combinations, 885
symposium, 813-1104

Mycobacterium avium, factors affecting the cell cycle, 914

Mycobacterium avium-intracellulare
characterization of plasmids, 949
lung infection
spectrum of clinical disease, 1046
surgical management, 1064
serovars isolated in South Africa, 1013

Mycobacterium avium-intracellulare-scrofulaceum
seroagglutination test in epidemiologic studies, 867

structures of typing antigens, 905

Mycobacterium avium complex, disease in animals, 960

Mycobacterium chelonei
infection treated with amikacin and doxycycline, 1068
susceptibility to sulfonamides, 898

Mycobacterium fortuitum
infection treated with amikacin and doxycycline, 1068
susceptibility to sulfonamides, 898

Mycobacterium intracellulare, infection
association with human leukocyte antigens, 1060
development of animal model, 973
treatment with multiple drug chemotherapy, 1052

Mycobacterium kansasi
infections in The Netherlands, 1024
lung disease
efficacies of various drugs, 1028
treatment with rifampin, 1035

Mycobacterium simiae, isolation and comparison to related mycobacteria, 1040

Mycobacterium tuberculosis, infections
in combination with atypical mycobacteria, 1081
vs. tuberculous disease, 1025

Nephrotic syndrome, and response to pneumococcal polysaccharide vaccine, S168, S184

Neutrophils and eosinophils, human, microbial mechanisms, 565

Nocardia, infections in immunocompromised cardiac allograft recipients, 492

Nosocomial infections
colonization with *P. cepacia*, 708
control, role of hospital administrator, 783, 785
cost-benefit analysis, 790
control and surveillance, 770, 775
environmental factors, 760
evaluation of antibiotic usage, 745, 754
hospital epidemiology
rates, case-finding and interpretation, 658
time and accuracy of estimation, 668
in a general hospital, surveillance, 649
in intensive care units, 716, 721
prevention by use of management techniques, 738
procedure-related, identification in high-risk patients, 701
statewide prospective surveillance system for identification and prevention, 683
surveillance and intervention in specific problem areas, 721
overview, 640
summary, 798

Nosocomial infection control, a symposium, 635-811

Otitis media
acute, recurrent, prevention by pneumococcal polysaccharide vaccine, S113, S119, S124
due to *S. pneumoniae*
in chinchillas, 342
in human children, 246

Ototoxicity, antibiotic-diuretic interventions in guinea pig model, S216

Pasteurization, as alternative to chlorination, 1255

Penicillin, phenoxyethyl, levels in human blood and interstitial fluid after oral administration, 121

Penicillin V, vs. bacampicillin and amoxicillin in treatment of tonsillitis and/or pharyngitis, 154

Phagocytic cells
abnormal chemotaxis, pathophysiology, clinical manifestations, and management of patients, 1196
cell-mediated immunity of, 1221
role in infection, 565

Pharmacokinetics
of antimicrobial agents, 4, 12, 19, 45
of ampicillin in serum and dermal suction blisters after oral administration of bacampicillin, 125
of bacampicillin and ampicillin in infants and children, 117

Plasmids, characterization, from strains of *M. avium-intracellulare*, 949

Pneumococcal polysaccharides, capsular, analysis of antibody, 543

Pneumococcal polysaccharide vaccine
age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines, S31
chemistry and immunochemistry, 518
clinical studies in infants
efficacy and effect on nasopharyngeal carriage, S108
prevention of recurrent otitis media, S113, S119, S124
reactogenicity and immunogenicity of two polyvalent vaccines, S97
control and immunogenicity of polysaccharides, S51
cross-reactions and immunology, S18
efficacy, S82
IgG and IgM response of patients with sickle cell disease, S179, S184
in the institutionalized elderly, S61, S184
design and results of a nonrandomized trial, S71
response of patients
with chronic obstructive pulmonary disease, S183
with diabetes mellitus, S191
with Hodgkin's disease, S133, S144, S160, S184
with nephrotic syndrome, S168
with renal failure and/or transplant, S168, S184
with splenectomy, S168, S184
with systemic lupus erythematosis, S184
serum antibody responses of high-risk children and adults, S168, S184. *See also specific risk factors, e.g. Diabetes mellitus*
symposium, S1-S197
toxicity, S184

Poliomyelitis, paralytic, old dogmas and new perspectives, 543

Poliiovirus vaccines, and "vaccine-associated" paralytic disease, 543

Polysaccharide antigens, of *S. pneumoniae*, immune response of mice and humans, 224, 323

Postantibiotic effect
leukocyte enhancement, increased susceptibility of antibiotic-treated bacteria to leukocyte activity, 38
suppression of growth of bacterial species by various antibiotics, 29

Pseudomonas cepacia, epidemic of nosocomial colonization, 708

Pulmonary disease. *See Lung infection*

Pulse dosing
of antimicrobial agents, especially bacampicillin, 1-177

theory and applications, 1

Radiolabeled microorganisms, comparison of different isotopes, 1179

Renal failure and/or transplant, and response to pneumococcal polysaccharide vaccine, S168, S184

Renal transplant patients, incidence and epidemiology of cytomegaloviral infections, 1151

Rimantadine, use in USSR, 408

Salmonella, antibiotic resistance in Europe and the United States, 1105

Salmonellosis, transmission of, 1105

Schaefer, W. B.

- Memorial Lecture, 953
- tribute, 813

Sensitins, use in classification and identification of mycobacteria, 944

Sepsis, experimental intraabdominal, comparison of efficacies of 29 antimicrobial regimens, 535

Sickle cell disease, IgG and IgM response to pneumococcal polysaccharide vaccine, S179

Spleen, role in immune response to *S. pneumoniae*, 224, 299

Splenectomy, and response to pneumococcal polysaccharide vaccine, S168, S184

Staphylococcal infections

- in children, treatment with vancomycin, S282
- treatment with vancomycin, S236, S293

Staphylococcus aureus, endocarditis, rabbit model, evaluation of antimicrobial agents, S240, S293

Staphylococcus aureus, infections, treatment with vancomycin, S200

Streptococcus, viridans group, endocarditis, rabbit model, evaluation of antimicrobial agents, S240, S293

Streptococcus pneumoniae

- bacteriophages, 212
- biology, disease, and prevention, S1
- epidemiology of disease, 233, 277
- antibiotic-resistant pneumococci, 254, 267
- in infants and children, 246
- in Papua New Guinea, 233
- experimental infections in animals, 342, 354
- history of research since 1875, 183
- host defense

 - complement and opsonins in serum and alveolar secretions of rats with pneumonia, 310
 - protection and pathogenesis of tissue damage, 282
 - regulation of response of thymus-derived cells to polysaccharide antigens, 232
 - response of mice and humans to polysaccharide antigens, 224, 323
 - role of complement, 289, 310
 - role of spleen, 299

- otitis media in chinchillas, efficacy of vaccination, 342
- polysaccharide antigens, immune response of mice and humans, 224, 323
- polysaccharide vaccine, symposium, S1-S197
- summary of conference, 358
- surface components, 190
- symposia

 - pneumococcal polysaccharide vaccine, S1-S197
 - the pneumococcus, 183-395

Strongyloides stercoralis, hyperinfection syndrome, 397

Sulfonamides, activity against *M. fortuitum* and *M. chelonei*, 898

Surgery

- and nosocomial infections, 721, 728
- antibiotic prophylaxis, 745, 754

Surgical wounds

- postoperative infection, multivariate analysis of determinants, basis for intervention, 678
- surveillance for infection, 734

Synergy, of antimicrobial agents, and assessment of drug combinations, 627

Systemic lupus erythematosus, and response to pneumococcal polysaccharide vaccine, S184

Toxicity

- of chloramphenicol, and current clinical usage, 479
- of pneumococcal polysaccharide vaccine, S184

Typhoid vaccination, introduction of, 1251

Urinary tract infection, treatment with amoxicillin, bacampicillin, or penicillin V, 154

Vancomycin

- absence of ototoxic effects in guinea pig model, S216
- adverse effects, S282, S293
- chemistry, S205, S293
- in combination with aminoglycoside, S210
- in combination with rifampin, S210
- history of development, S199, S200, S293
- introduction to symposium, S199
- for patients with renal insufficiency, S230
- penetration into cerebrospinal fluid, S289
- pharmacokinetics, S293
- in anephric patients, S269
- in normal subjects, S230, S269
- in patients with reduced renal function, S230, S269
- pharmacology and efficacy for staphylococcal infections in children, S282
- for prophylaxis

 - in anephric patients, S269
 - in patients with cancer, S259
 - in patients with malignancy, S293
 - in renal dialysis patients, S200

- in rabbit model of endocarditis due to *S. aureus* or viridans group streptococcus, S240
- spectrum and antibacterial action, S210, S293
- structure, S205
- summary of symposium, S293
- symposium, S199-S300
- toxicology, in laboratory animals, S224
- for treatment

 - of antibiotic-associated enterocolitis, S273, S293
 - of bacterial meningitis, S289, S293
 - of infective endocarditis due to staphylococci or streptococci, S250, S293
 - of *S. aureus* infections, S200
 - of staphylococcal infections

 - in children, S282
 - severe, S236

Reviews of Infectious Diseases

An Official Publication of the Infectious Diseases Society of America

Edward H. Kass, *Editor*

John R. David, *Associate Editor*

Sherwood L. Gorbach, *Associate Editor*

Alice S. Huang, *Associate Editor*

Dennis L. Kasper, *Associate Editor*

Jerome O. Klein, *Associate Editor*

EDITORIAL BOARD

Robert Austrian, Philadelphia, Pa.

Michael M. Frank, Bethesda, Md.

Lawrence R. Freedman, Los Angeles, Calif.

D. Carleton Gajdusek, Bethesda, Md.

King K. Holmes, Seattle, Wash.

Harold J. Jennings, Ottawa, Canada

INTERNATIONAL BOARD OF DIRECTORS

Jacques F. Acar, Paris, France

Ralph van Furth, Leiden, The Netherlands

C. H. Huang, Beijing, China

Lars O. Kallings, Stockholm, Sweden

Jean Klastersky, Brussels, Belgium

Mary M. Eichhorn Adams, *Assistant Editor*

Nancy Kurz Voynow, *Managing Editor*

Maureen A. Hayes, *Editorial Assistant*

Louise L. Kittredge, *Editorial Assistant*

Laura J. Liebler, *Editorial Assistant*

Richard T. Johnson, Baltimore, Md.

Samuel L. Katz, Durham, N.C.

Thomas C. Merigan, Jr., Stanford, Calif.

Kenneth S. Warren, New York, N.Y.

Frank E. Young, Rochester, N.Y.

P. Helena Mäkelä, Helsinki, Finland

Francis O'Grady, Nottingham, England

Theodore G. Sacks, Jerusalem, Israel

David A. J. Tyrrell, London, England

Yuichi Yamamura, Osaka, Japan

Volume 3
January-December 1981

I
N
D
E
X

All rights reserved

THE UNIVERSITY OF CHICAGO PRESS, CHICAGO
THE UNIVERSITY OF CHICAGO PRESS LTD., LONDON S.W. 1

© 1981 BY THE UNIVERSITY OF CHICAGO
PUBLISHED BIMONTHLY JANUARY-DECEMBER

Printed in U.S.A.

Reviews of Infectious Diseases

Volume 3

January-February 1981

Number 1

Contents

Participants	vi
Theory and Applications of Pulse Dosing: A Summary of the Symposium. WILLIAM M. M. KIRBY and WILLIAM A. CRAIG	1
Historical Background and Current Practices	
Dosage Schedules of Antimicrobial Agents: A Historical Review. CALVIN M. KUNIN	4
Current Practices in Antimicrobial Dosing. HAROLD C. NEU	12
Microbiologic Considerations	
Kinetics of Antimicrobial Action. H. MATTIE	19
Postantibiotic Suppression of Bacterial Growth. ROBERT W. BUNDTZEN, ANDREAS U. GERBER, DAVID L. COHN, and WILLIAM A. CRAIG	28
Postantibiotic Leukocyte Enhancement: Increased Susceptibility of Bacteria Pretreated with Antibiotics to Activity of Leukocytes. P. J. McDONALD, B. L. WETHERALL, and H. PRUUL	38
Pharmacologic Considerations	
Pharmacokinetics of Tissue Penetration of Antibiotics. TOM BERGAN	45
Penetration of Antibiotics into Respiratory Secretions. JAMES E. PENNINGTON	67
In Vivo Studies	
Comparative Studies of Intermittent and Continuous Administration of Aminoglycosides in the Treatment of Bronchopulmonary Infections Due to Gram-Negative Bacteria. J. KLASTERSKY, J. P. THYS, and G. MOMBELLI	74
Continuous vs. Intermittent Administration of Antimicrobial Agents: Tissue Penetration and Efficacy in Vivo. MICHEL G. BERGERON, DENIS BEAUCHAMP, ANDRÉ POIRIER, and ALAIN BASTILLE	84
Intermittent or Continuous Therapy of Experimental Meningitis Due to <i>Streptococcus pneumoniae</i> in Rabbits: Preliminary Observations on the Postantibiotic Effect in Vivo. MERLE A. SANDE, OKSANA M. KORZENIOWSKI, GEORGE M. ALLEGRO, ROBERT O. BRENNAN, OTOKAR ZAK, and W. MICHAEL SCHELD	98
Bacampicillin: Pharmacologic Studies	
The Pharmacokinetics of Bacampicillin. HAROLD C. NEU	110
Comparative Pharmacokinetics of Bacampicillin and Ampicillin Suspensions in Infants and Children. CHARLES M. GINSBURG, GEORGE H. McCracken, JR., JOAN CLAHSEN, and TERESA ZWEIGHAFT	117
Levels of Antibiotic in Human Blood and Interstitial Fluid After Oral Administration of Bacampicillin or Phenoxyethyl Penicillin and Intravenous Administration of Amoxicillin or Ampicillin. JAMES S. TAN, SARA-JANE SALSTROM, and THOMAS M. FILE, JR	121

Bacampicillin: Clinical Studies	
Pharmacokinetics of Ampicillin in Serum and in Dermal Suction Blisters After Oral Administration of Bacampicillin. A. SCHREINER, T. BERGAN, K. B. HELLUM, and A. DIGRANES.....	125
Pulse Dosing with Bacampicillin in Treatment of Acute Exacerbations of Chronic Bronchitis. F. P. V. MAESEN and B. I. DAVIES.....	132
Comparison of Bacampicillin Twice Daily and Ampicillin Four Times Daily in Treatment of Acute Exacerbations of Chronic Bronchitis. SANFORD CHODOSH.....	140
Controlled Comparative Trial of Bacampicillin and Amoxicillin in Therapy of Bacterial Infections of the Lower Respiratory Tract. SYDNEY M. FINEGOLD, LAYNE O. GENTRY, WILLIAM MOGABGAB, SAMMY C. CAMPBELL, and JAMES SKATRUD	150
A Comparative Study of Bacampicillin Hydrochloride, Penicillin V, and Amoxicillin in the Treatment of Acute Tonsillitis and/or Pharyngitis Due to β -Hemolytic Streptococci. GEORGE A. PANKEY, CHARLES GLEASON, THOMAS M. FILE, JR., and WALTER BROWN	154
Bacampicillin vs. Amoxicillin for Treatment of Acute Infections of the Urinary Tract. GEORGE A. RICHARD, ABDOLLAH IRAVANI, JACK L. LEFROCK, and WILLIAM MOGABGAB.....	159
Clinical Evaluation of Single-Dose Oral Bacampicillin or Ampicillin in Therapy of Uncomplicated Gonorrhea. KENNETH F. WAGNER, GEORGE COUNTS, KING K. HOLMES, P. FREDERICK SPARLING, LAYNE O. GENTRY, and LARRY EDWARDS.....	166
A Comparative Study of Bacampicillin Hydrochloride Given Twice a Day and Amoxicillin Given Three Times a Day for Treatment of Skin and Soft Tissue Infections: Preliminary Observations. E. WILLIAM ROSENBERG	170
Worldwide Experience with Bacampicillin Administered Twice a Day. WILLIAM A. CRAIG and ANDREAS U. GERBER.....	171
Statement of Editorial Policy and Instructions to Authors.....	178

Volume 3

March-April 1981

Number 2

Contents

Participants	vi
Session I: The Pneumococcus	
Pneumococcus: The First One Hundred Years. ROBERT AUSTRIAN.....	183
Discussion	189
Surface Components of <i>Streptococcus pneumoniae</i> . ALEXANDER TOMASZ.....	190
Bacteriophages of <i>Streptococcus pneumoniae</i> . RUBENS LOPEZ, ERNESTO GARCIA, and CONCEPCION RONDA.....	212
Immune Responses to Pneumococcal Polysaccharide Antigens: A Comparison of the Murine Model and the Response in Humans. GERALD SCHIFFMAN.....	224
Discussion	232

Session II: Epidemiology of Pneumococcal Disease

An Epidemiologic Approach to Pneumococcal Disease. IAN D. RILEY and ROBERT M. DOUGLAS.....	233
The Epidemiology of Pneumococcal Disease in Infants and Children. JEROME O. KLEIN.....	246
Antibiotic-Resistant <i>Streptococcus pneumoniae</i> : Clinical and Epidemiologic Aspects. JOEL WARD.....	254
Multiple Antibiotic Resistance in South African Strains of <i>Streptococcus pneumoniae</i> : Mechanism of Resistance to β -Lactam Antibiotics. SONIA ZIGHELBOIM and ALEXANDER TOMASZ.....	267
Discussion	276
Epidemiology of Clinically Significant Isolates of <i>Streptococcus pneumoniae</i> in the United States. CLAIRE V. BROOME and RICHARD R. FACKLAM.....	277
Discussion	281

Session III: Host Defense Against the Pneumococcus

The Host Response to Invasion by <i>Streptococcus pneumoniae</i> : Protection and the Pathogenesis of Tissue Damage. RICHARD B. JOHNSTON, JR.....	282
The Role of Complement in the Host's Defense Against <i>Streptococcus pneumoniae</i> . JERRY A. WINKELSTEIN.....	289
Discussion	298
Host Defense Against <i>Streptococcus pneumoniae</i> : The Role of the Spleen. DIANE W. WARAS.....	299
Discussion	309
Complement and Opsonins in Alveolar Secretions and Serum of Rats with Pneumonia Due to <i>Streptococcus pneumoniae</i> . J. DONALD COONROD and KOKICHI YONEDA.....	310
Chemical Structure of and Immune Response to Polysaccharides of <i>Streptococcus pneumoniae</i> . CHI-JEN LEE, BLAIR A. FRASER, SHOUSUN SZU, and KUEI-TANG LIN.....	323
Regulation of the Antibody Response to Pneumococcal Polysaccharide by Thymus-Derived Cells. PHILLIP J. BAKER, DIANA F. AMSBAUGH, PHILIP W. STASHAK, GEORGE CALDES, and BENJAMIN PRESCOTT.....	332
Discussion	341
The Pathogenesis of Pneumococcal Otitis Media in Chinchillas and the Efficacy of Vaccination in Prophylaxis. G. SCOTT GIEBINK.....	342
Discussion	353
Experimental Infections of Animals in the Study of <i>Streptococcus pneumoniae</i> . E. RICHARD MOXON	354

Summary

Conference on the Pneumococcus: Summary and Comments. MAXWELL FINLAND.....	358
--	-----

Classics in Infectious Diseases

The Significance of Pneumococcal Types. FRED. GRIFFITH.....	372
Errata (Bergan, T., 3:45-66; Schreiner, A., et al., 3:125-131).....	396

Contents

Participants	Svi
Session I: Pneumococcal Disease and the Development and Chemistry of the Vaccine	
Some Observations on the Pneumococcus and on the Current Status of Pneumococcal Disease and Its Prevention. ROBERT AUSTRIAN	S1
Chemistry and Immunochemistry of the Pneumococcal Polysaccharide Vaccine with Special Reference to Cross-Reactions and Immunologic Factors. GERALD SCHIFFMAN	S18
Discussion	S27
Session II: Responses to Pneumococcal Vaccine	
<i>Streptococcus pneumoniae</i> Polysaccharide Vaccine: Age and Dose Responses, Safety, Persistence of Antibody, Revaccination, and Simultaneous Administration of Pneumococcal and Influenza Vaccines. MAURICE R. HILLEMAN, ALFRED J. CARLSON, JR., ARLENE A. MCLEAN, PHILIP P. VELLA, ROBERT E. WEIBEL, and ALLEN F. WOODHOUR	S31
Summarized vs. Type-Specific Analysis of Antibody to Pneumococcal Capsular Polysaccharides. G. SCOTT GIEBINK, CHAP T. LE, and JOHN S. SPIKA	S43
Discussion	S47
Session III: Efficacy of Pneumococcal Vaccine	
Studies on Vaccine Control and Immunogenicity of Polysaccharides of <i>Streptococcus pneumoniae</i> . CHI-JEN LEE and KUEI-TANG LIN	S51
Discussion	S60
Pneumococcal Vaccine in the Institutionalized Elderly: Review of Past and Recent Studies. DAVID W. BENTLEY	S61
Pneumococcal Vaccine in the Institutionalized Elderly: Design of a Nonrandomized Trial and Preliminary Results. DAVID W. BENTLEY, KATHY HA, KENNETH MAMOT, DAVID MOON, LORRAINE MOORE, PATRICIA POLETTI, and AUDREY SPRINGETT	S71
Efficacy of Pneumococcal Polysaccharide Vaccines. CLAIRE V. BROOME	S82
Discussion	S89
Session IV: Efficacy Studies of Pneumococcal Vaccine in Infants and Children	
Clinical Studies of Pneumococcal Vaccines in Infants. I. Reactogenicity and Immunogenicity of Two Polyvalent Polysaccharide Vaccines. SARAH H. SELL, PETER F. WRIGHT, WILLIAM K. VAUGHN, JULIETTE THOMPSON, and GERALD SCHIFFMAN	S97
Clinical Studies of Pneumococcal Vaccines in Infants. II. Efficacy and Effect on Nasopharyngeal Carriage. PETER F. WRIGHT, SARAH H. SELL, WILLIAM K. VAUGHN, CLAUDIA ANDREWS, KATHRYN B. McCONNELL, and GERALD SCHIFFMAN	S108
Use of Pneumococcal Vaccine for Prevention of Recurrent Acute Otitis Media in Infants in Boston. DAVID W. TEELE, JEROME O. KLEIN, and the GREATER BOSTON COLLABORATIVE STUDY GROUP: LORNA BRATTON, GILBERT R. FISCH, OWEN R. MATHIEU, PHILIP J. PORTER, SIDNEY G. STAROBIN, LLOYD D. TARLIN, and ROBERT P. YOUNES	S113

Efficacy of Pneumococcal Polysaccharide Vaccine in Preventing Acute Otitis Media in Infants in Huntsville, Alabama. JOHN L. SLOYER, JR., JOHN H. PLOUSSARD, and VIRGIL M. HOWIE	S119
A Study of the Pneumococcal Vaccine in Prevention of Clinically Acute Attacks of Recurrent Otitis Media. P. HELENA MÄKELÄ, MAIJA LEINONEN, JUHANI PUKANDER, and PEKKA KARMA	S124
Discussion	S131
Session V: Immunologic Response of High-Risk Patients to Pneumococcal Vaccine	
Response to Pneumococcal Vaccine Among Children with Hodgkin's Disease. SARAH S. DONALDSON, KENNETH L. VOSTI, F. RALPH BERBERICH, RICHARD S. COX, HENRY S. KAPLAN, and GERALD SCHIFFMAN	S133
Antibody Response of Patients with Hodgkin's Disease to Protein and Polysaccharide Antigens. GEORGE R. SIBER, SIGMUND A. WEITZMAN, and ALAN C. AISENBERG	S144
Immunization of Immunosuppressed Patients with Pneumococcal Polysaccharide Vaccine. ARTHUR J. AMMANN, GERALD SCHIFFMAN, JOSEPH E. ADDIEGO, WILLIAM M. WARAS, and DIANE W. WARAS	S160
Serum Antibody Responses of High-Risk Children and Adults to Vaccination with Capsular Polysaccharides of <i>Streptococcus pneumoniae</i> . G. SCOTT GIEBINK, CHAP T. LE, FERNANDO G. COSIO, JOHN S. SPIKA, and GERALD SCHIFFMAN	S168
Pneumococcal Vaccine in Sickle Cell Disease: IgG and IgM Antibody Response. DOUGLAS J. BARRETT and ARTHUR J. AMMANN	S179
Pneumococcal Antibodies in Patients with Chronic Obstructive Pulmonary Disease and Their Response to Pneumococcal Capsular Polysaccharides: Preliminary Results. ANNE L. DAVIS, CONRADO ARANDA, LYNN CHRISTIANSON, and GERALD SCHIFFMAN	S183
Assessment of the Antibody Response to Pneumococcal Vaccine in High-Risk Populations. SHELDON H. LANDESMAN and GERALD SCHIFFMAN	S184
Discussion	S197

Volume 3

May-June 1981

Number 3

Contents

Review Articles

Syndrome of Hyperinfection with <i>Strongyloides stercoralis</i> . YARDENA IGRA-SIEGMAN, RAJENDRA KAPILA, PURNENDU SEN, ZIGMUND C. KAMINSKI, and DONALD B. LOURIA	397
Study of Rimantadine in the USSR: A Review of the Literature. D. M. ZLYDNIKOV, O. I. KUBAR, T. P. KOVALEVA, and L. E. KAMFORIN	408
The Immunology of Leprosy: Speculations on the Leprosy Spectrum. P. SANSONETTI and P. H. LAGRANGE	422
The Importance of Lactic Acid Levels in Body Fluids in the Detection of Bacterial Infections. ITZHAK BROOK	470
Chloramphenicol: A Review of Its Use in Clinical Practice. HENRY M. FEDER, JR., CARL OSIER, and EUFRONIO G. MADERAZO	479

Nocardial Infections in the Immunocompromised Host: A Detailed Study in a Defined Population. GARY L. SIMPSON, EDWARD B. STINSON, MARLENE J. EGGER, and JACK S. REMINGTON	492
Direct Effects of Hyperthermia on Pathogenic Microorganisms: Teleologic Implications with Regard to Fever. PHILIP A. MACKOWIAK	508
Secretory Immunity and the Bacterial IgA Proteases. STEPHEN J. KORNFELD and ANDREW G. PLAUT	521
Therapeutic Efficacy of 29 Antimicrobial Regimens in Experimental Intraabdominal Sepsis. JOHN G. BARTLETT, THOMAS J. LOUIE, SHERWOOD L. GORBACH, and ANDREW B. ONDERDONK ..	535
Paralytic Poliomyelitis: Old Dogmas and New Perspectives. ALBERT B. SABIN	543

Serial Features

The Microbicidal Mechanisms of Human Neutrophils and Eosinophils. RICHARD K. ROOT and MYRON S. COHEN	565
Gram-Negative Anaerobic Bacilli: Their Role in Infection and Patterns of Susceptibility to Antimicrobial Agents. II. Little-Known <i>Fusobacterium</i> species and Miscellaneous Genera. W. LANCE GEORGE, BARBARA D. KIRBY, VERA L. SUTTER, DIANE M. CITRON, and SYDNEY M. FINEGOLD	599

Hypothesis

The Assessment of Antimicrobial Combinations. THOMAS C. KING, DAVID SCHLESSINGER, and DONALD J. KROGSTAD	627
--	-----

Volume 3

July-August 1981

Number 4

Contents

Participants	vi
Introduction. THEODORE SACKS	635
The Hospital in Jewish History. SAMUEL S. KOTTEK	636
Session I	
Nosocomial Infection Control: An Overview. PHILIP S. BRACHMAN	640
A Program for Surveillance of Hospital-Acquired Infections in a General Hospital: A Two-Year Experience. NACHUM EGOZ and DAN MICHAELI	649
Methodologic Issues in Hospital Epidemiology. JONATHAN FREEMAN and JOHN E. McGOWAN, JR.	
I. Rates, Case-Finding, and Interpretation	658
II. Time and Accuracy of Estimation	668
Multivariate Analysis of Determinants of Postoperative Wound Infection: A Possible Basis for Intervention. E. SIMCHEN, M. SHAPIRO, J. MICHEL, and T. SACKS	678

Rationale and Methods for a Statewide, Prospective Surveillance System for the Identification and Prevention of Nosocomial Infections. IRA B. TAGER, MICHAEL B. GINSBERG, ELISHEVA SIMCHEN, LILLIAN MIAO, KATHLEEN HOLBROOK, and GERALD A. FAICH.....	683
Discussion	694
 Session II	
Identification of Procedure-Related Nosocomial Infections in High-Risk Patients. RICHARD P. WENZEL, CHARLES A. OSTERMAN, LEIGH G. DONOWITZ, JOHN W. HOYT, MERLE A. SANDE, WILLIAM J. MARTONE, JAMES E. PEACOCK, JR., JULES I. LEVINE, and GRAYSON B. MILLER, JR....	701
<i>Pseudomonas cepacia</i> : Implications of Epidemic Nosocomial Colonization. WILLIAM J. MARTONE, CHARLES A. OSTERMAN, KAREN A. FISHER, and RICHARD P. WENZEL.....	708
Contaminated Breast Milk: A Source of <i>Klebsiella</i> Bacteremia in a Newborn Intensive Care Unit. LEIGH G. DONOWITZ, FREDERIC J. MARSIK, KAREN A. FISHER, and RICHARD P. WENZEL	716
Program for Surveillance and Intervention in Specific Problem Areas of Nosocomial Infections. LARS O. KALLINGS	721
Control of Infection in the Hospital: Problems in Surgery and the Management of Burns. E. J. L. LOWBURY.....	728
Wound Infection Surveillance. PETER CRUSE.....	734
Preventing Nosocomial Infection through the Use of Effective Management Techniques. BARBARA A. TERRY.....	738
Discussion	742
 Session III	
Evaluation of Antibiotic Usage: A Comprehensive Look at Alternative Approaches. CALVIN M. KUNIN.....	745
Antibiotic Use on the Surgical Services of Two Jerusalem Hospitals, as Determined by Surveillance and Influenced by an Intervention Program. M. SHAPIRO, T. SACKS, E. SIMCHEN, J. MICHEL, and B. RUDENSKY.....	754
Environmental Factors in Nosocomial Infection—A Selective Focus. JOHN E. McGOWAN, JR.	760
Do You Practice What You Preach? ELIZABETH A. JENNER.....	770
The Usefulness of a Conceptual Model in the Study of the Efficacy of Infection Surveillance and Control Programs. ROBERT W. HALEY.....	775
Discussion	781
 Session IV	
Nosocomial Infection Control: Role of the Hospital Administrator. PHILIP S. BRACHMAN and ROBERT W. HALEY.....	783
The Role of the Hospital Administrator in the Control of Nosocomial Infections. LEON EPSTEIN.....	785
Cost and Benefit in Control of Nosocomial Infection: Methods for Analysis. JOHN E. McGOWAN, JR.....	790
 Session V	
International Symposium on Control of Nosocomial Infections: Synthesis and Summary. THEODORE C. EICKHOFF.....	798

General Discussion.....	804
Classics in Infectious Diseases	
The Etiology, the Concept and the Prophylaxis of Childbed Fever. IGNAZ PHILIPP SEMMELWEIS	808
Notice.....	812
Errata (Finland, M., 3:358-371)	812
Volume 3 • September-October 1981 • Number 5	
Contents	
Tribute to Werner B. Schaefer. GERTRUD MEISSNER.....	813
Participants	814
Introduction. PAUL T. DAVIDSON.....	816
Keynote Session	
Mycobacteria: An Overview. ERNEST H. RUNYON.....	819
Session I: Classification and Identification	
Numerical Taxonomy and Cooperative Studies: Roles and Limits. LAWRENCE G. WAYNE....	822
Some Considerations Regarding the Classification and Identification of Mycobacteria. MICHIO TSUKAMURA	829
A Review of the Methods of Identification and Differentiation of Mycobacteria. MICHIO TSUKAMURA	841
Lipid Analysis for the Identification of Mycobacteria: An Appraisal. PETER A. JENKINS.....	862
Session II: Identification and Laboratory Characteristics	
The Seroagglutination Test in the Study of Nontuberculous Mycobacteria. J. KENNETH MCCATCHY.....	867
Application of Pyrolysis Mass Spectrometry to the Classification and Identification of Mycobacteria. G. WIETEN, J. HAVERKAMP, H. W. B. ENGEL, and L. G. BERWALD.....	871
Basis for Lack of Drug Susceptibility of Atypical Mycobacteria. HUGO L. DAVID.....	878
In Vitro and In Vivo Susceptibility of Atypical Mycobacteria to Various Drugs. FUMIYUKI KUZE, TAKUYA KURASAWA, KENJI BANDO, YOUNGCHOL LEE, and NOBUO MAEKAWA.....	885
Sulfonamide Activity Against <i>Mycobacterium fortuitum</i> and <i>Mycobacterium chelonei</i> . RICHARD J. WALLACE, JR., DAN B. JONES, and KAREN WISS.....	898
Session III: Bacteriology	
Structures of the Typing Antigens of Atypical Mycobacteria: A Brief Review of Present Knowledge. PATRICK J. BRENNAN.....	905
Factors that Affect the Cell Cycle of <i>Mycobacterium avium</i> . CHARLOTTE McCARTHY and PATRICK ASHBAUGH.....	914

Agents of Mycobacterial Variation. EDITH MANKIEWICZ.....	926
Antigenic Relationships among Mycobacterial Species Studied by Modified-Rocket and Crossed Immunolectrophoresis. SOTIROS D. CHAPARAS.....	934
Mycobacterial Sensitins: Where Are We Now? MOGENS MAGNUSSON.....	944
Characterization of Plasmids from Strains of <i>Mycobacterium avium-intracellulare</i> . JACK T. CRAWFORD, M. DONALD CAVE, and JOSEPH H. BATES.....	949
Session IV: Animal Infections	
The Value of Animal Models for Study of Infection Due to Atypical Mycobacteria. The Schaefer Memorial Lecture. GERTRUD MEISSNER.....	953
Mycobacterial Infections in Animals. CHARLES O. THOEN, ALFRED G. KARLSON, and ELMER M. HIMES.....	960
Experimental Infections with <i>Mycobacterium intracellulare</i> . PATTISAPU R. GANGADHARAM, PHILIP F. PRATT, and PAUL T. DAVIDSON.....	973
Pathogenicity and Immunogenicity of Atypical Mycobacteria for Calves: A Short Summary. J. BERG JØRGENSEN.....	979
Immune Responses to Atypical Mycobacterial Lung Infections. FRANK M. COLLINS and SUSAN R. WATSON.....	981
Session V: Epidemiology	
Recent Experience in the Epidemiology of Disease Caused by Atypical Mycobacteria. HOWARD GRUFT, JOSEPH O. FALKINHAM III, and BRUCE C. PARKER.....	990
Epidemiologic Studies of Lung Disease Due to Mycobacteria Other than <i>Mycobacterium tuberculosis</i> in Japan. MICHIO TSUKAMURA, HISAO SHIMOIDE, NOBUHIKO KITA, KEISHI KAWAKAMI, TADAO ITO, NAOTO NAKAJIMA, HIROKO KONDO, YOSHITAKA YAMAMOTO, NOBURO MATSUDA, MASATOSHI TAMURA, KAZUO YOSHIMOTO, NOBUMITSU SHIROTA, and AKIHIKO KUSE.....	997
Epidemiology of Mycobacteria Other than Tubercle Bacilli in South Africa. H. H. KLEEBERG	1008
<i>Mycobacterium avium-intracellulare</i> Complex Serovars Isolated in South Africa from Humans, Swine, and the Environment. ELLEN E. NEL.....	1013
The Epidemiology of Opportunist Mycobacterial Infections in Wales, 1952-1978. PETER A. JENKINS.....	1021
<i>Mycobacterium kansasii</i> Infections in The Netherlands: A Brief Summary. H. W. B. ENGEL, L. C. BERWALD, B. W. LINDEBOOM, and A. H. HAVELAAR.....	1024
Session VI: Clinical Aspects	
Editorial. When is an Infection Disease? EMANUEL WOLINSKY.....	1025
Chemotherapy for Pulmonary Disease Due to <i>Mycobacterium kansasii</i> : Efficacies of Some Individual Drugs. CHAI H. AHN, JAMES R. LOWELL, SAM S. AHN, SUZANNE AHN, and GEORGE A. HURST.....	1028
Treatment of Pulmonary Disease Due to <i>Mycobacterium kansasii</i> : Recent Experience with Rifampin. WILLY PEZZIA, JAMES W. RALEIGH, MARGARET C. BAILEY, ELIZABETH A. TOTH, and JULIAN SILVERBLATT.....	1035
<i>Mycobacterium simiae</i> and Related Mycobacteria. J. G. WEISZFEILER, V. KARASSEVA, and E. KARCZAG.....	1040
Spectrum of Clinical Disease in Pulmonary Infection with <i>Mycobacterium avium-intracellulare</i> . DAVID Y. ROSENZWEIG and DONALD P. SCHLUETER.....	1046

Treatment of Disease Due to <i>Mycobacterium intracellulare</i> . PAUL T. DAVIDSON, VINOD KHANJO, MARIAN GOBLE, and THOMAS S. MOULDING.....	1052
Disease Due to <i>Mycobacterium intracellulare</i> : Its Possible Association with Human Leukocyte Antigens. ANUP K. CHAKRABORTY, PRADEEP B. DAMLE, PAUL T. DAVIDSON, and ROBERT T. MCCALMON	1060
Surgical Management of Pulmonary Disease Due to <i>Mycobacterium avium-intracellulare</i> . RAYMOND F. CORPE.....	1064
Clinical Usefulness of Amikacin and Doxycycline in the Treatment of Infection Due to <i>Mycobacterium fortuitum</i> and <i>Mycobacterium chelonei</i> . JOSEPH R. DALOVISIO, GEORGE A. PANKEY, RICHARD J. WALLACE, and DAN B. JONES.....	1068
Editorial. Atypical Mycobacterial Infections in Children. KATHARINE H. K. HSU.....	1075
Mixed Mycobacterial Infections. J. G. WEISZFEILER and V. KARASSEVA.....	1081
Nontuberculous Mycobacteria in Sweden: A Brief Summary. INGELA SJÖGREN.....	1084
Pulmonary Infection Caused by Atypical Mycobacteria: A Report of 24 Cases in Thailand. NADDA SRIYABHAYA and SРИBUSAYA WONGWATANA.....	1085
Pulmonary Disease Due to Atypical Mycobacteria: A Retrospective Study from South India. C. V. RAMAKRISHNAN.....	1090
Discussion	1093
Classics in Infectious Diseases	
The Relationship of "Atypical" Acid-Fast Bacteria to Human Disease: A Preliminary Report. ALICE TIMPE and ERNEST H. RUNYON.....	1098
Errata (Zlydnikov, D. M. et al. 3:408-421).....	1104

Volume 3

November-December 1981

Number 6

Contents

Review Articles

Antibiotic Resistance of <i>Salmonella</i> in Europe and the United States. CHARLES E. CHERUBIN ..	1105
The Significance of Iron in Infection. J. J. BULLEN	1127
Actinomycetoma in the United States. ROBERT R. TIGHT and MARILYN S. BARTLETT	1139
Cytomegalovirus Infections Following Renal Transplantation. JERRY GLENN.....	1151
Radiolabeled Microorganisms: Comparison of Different Radioisotopic Labels. RAJ KISHORE ..	1179
Isolation and Characterization of a Human Fibroblast Interferon Gene and Its Expression in <i>Escherichia coli</i> . RIK DERYNCK, RENÉ DEVOS, ERIK REMAUT, ERIK SAMAN, PATRICK STANSSENS, JAN TAVERNIER, GUIDO VOLCKAERT, JEAN CONTENT, ERIK DE CLERCQ, and WALTER FIERS	1186

Serial Feature

Abnormal Phagocyte Chemotaxis: Pathophysiology, Clinical Manifestations, and Management of Patients. JOHN I. GALLIN	1196
---	------

The Role of Cell-Mediated Immunity in Bacterial Infections. HELMUT HAHN and STEFAN H. E. KAUFMANN	1221
---	------

Historical Article

Who Introduced Typhoid Vaccination: Almroth Wright or Richard Pfeiffer? DIETER H. M. GRÖSCHEL and RICHARD B. HORNICK	1251
--	------

Correspondence

Alternatives to Water Chlorination. HANS H. NEUMANN	1255
Reviewers for Volume 3	1258
Index to Volume 3	1261

Volume 3 • November-December 1981 • Supplement

Contents

Introduction to the Symposium. ROBERT I. WISE	S199
---	------

Session I: History, Bacteriology, and Animal Toxicity

Introduction to Vancomycin. RICHARD S. GRIFFITH	S200
Structural Features of Vancomycin. RALPH R. PFEIFFER	S205
The Antibacterial Action of Vancomycin. CHATRCHAI WATANAKUNAKORN	S210
Effects of Antibiotic-Diuretic Interactions in the Guinea Pig Model of Ototoxicity. ROBERT E. BRUMMETT	S216
Toxicology of Vancomycin in Laboratory Animals. JOHN S. WOLD and STANLEY A. TURNIPSEED	S224

Session II: Clinical Pharmacology and Clinical Use

Pharmacokinetics of Vancomycin in Normal Subjects and in Patients with Reduced Renal Function. ROBERT C. MOELLERING, JR., DONALD J. KROGSTAD, and DAVID J. GREENBLATT ..	S230
Vancomycin Therapy in Severe Staphylococcal Infections. WILLIAM M. M. KIRBY	S236
Evaluation of Antimicrobial Agents in the Rabbit Model of Endocarditis. MERLE A. SANDE	S240
Vancomycin Therapy for Infective Endocarditis. JOSEPH E. GERACI and WALTER R. WILSON	S250
Antibiotic Prophylaxis in Cancer Patients: Regimens of Oral, Nonabsorbable Antibiotics for Prevention of Infection During Induction of Remission. GERALD P. BODEY	S259
Pharmacokinetics of Vancomycin in Anuria. B. A. CUNHA, R. QUINTILIANI, J. M. DEGLIN, M. W. IZARD, and C. H. NIGHTINGALE	S269
Treatment of Antibiotic-Associated Enterocolitis with Vancomycin. ROBERT FEKETY, JOSEPH SILVA, JOHN ARMSTRONG, MARIA ALLO, ROBERT BROWNE, JOHN EBRIGHT, RODNEY LUSK, GARY RIFKIN, and RENU TOSHNIWAL	S273

Pharmacology and Efficacy of Vancomycin for Staphylococcal Infections in Children. URIS B. SCHAAD, JOHN D. NELSON, and GEORGE H. McCACKEN, JR	S282
Vancomycin for Treatment of Bacterial Meningitis. DIETER W. GUMP.....	S289
Summary	
The Vancomycin Symposium: Summary and Comments. ROBERT I. WISE.....	S293

